![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
How to Spend $95 in Biotech – Analyst Blog
Zacks Market Commentaries (March 17th, 2009) Writes:
Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors.We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech.Antisense Makes a Lot of SenseFor a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense technology.We've made it no secret in the past -- we are big fans of antisense. We view the drug discovery engine fueled by Isis' antisense technology very similar to the power of Genentech's recombinant DNA and monoclonal antibody technology breakthroughs of the 1980's. Antisense drugs are still in their infancy, ...
Tags for this Post:
adult stem cell product;, antisense ;, antisense technology;, Aventis, Biogen Idec, Biotechnology, biotechnology investors;, biotechnology stocks;, Blog Sometime;, cancer, chronic obstructive pulmonary disease;, coronary artery disease, Crohn's disease, Cypress Biosciences, Cystic Fibrosis, Diabetes, Drug Discovery, Fda, Fibromyalgia, Genzyme, Glaxosmithkline, graft-vs-host disease;, hepatitis, Isis Pharmaceuticals;, Isis;, Johnson, leap-forward product;, migraine, migraine headaches;, Mississippi, monoclonal antibody technology breakthroughs;, Multiple Sclerosis, Myocardial Infarction, one drug;, Pfizer, recombinant DNA;, respective product;, Spinal Cord Injury, Stem Cells, Stocks to Watch, ulcerative colitis;, United States, USD, Zacks Market Commentaries
adult stem cell product;, antisense ;, antisense technology;, Aventis, Biogen Idec, Biotechnology, biotechnology investors;, biotechnology stocks;, Blog Sometime;, cancer, chronic obstructive pulmonary disease;, coronary artery disease, Crohn's disease, Cypress Biosciences, Cystic Fibrosis, Diabetes, Drug Discovery, Fda, Fibromyalgia, Genzyme, Glaxosmithkline, graft-vs-host disease;, hepatitis, Isis Pharmaceuticals;, Isis;, Johnson, leap-forward product;, migraine, migraine headaches;, Mississippi, monoclonal antibody technology breakthroughs;, Multiple Sclerosis, Myocardial Infarction, one drug;, Pfizer, recombinant DNA;, respective product;, Spinal Cord Injury, Stem Cells, Stocks to Watch, ulcerative colitis;, United States, USD, Zacks Market Commentaries
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.